@article{article_320124, title={Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II}, journal={Erzincan University Journal of Science and Technology}, volume={10}, pages={1–10}, year={2017}, DOI={10.18185/erzifbed.320124}, author={Dilek, Esra and Çankaya, Murat and Ezmeci, Talat and Sunar, Mukadder and Çoban, T. Abdulkadir}, keywords={Rivastigmine,galantamine,inhibition,carbonic anhydrases}, abstract={<p class="MsoNormal" style="line-height:150%;"> <span lang="en-us" style="font-family:Georgia, serif;" xml:lang="en-us">The carbonic
anhydrases (CA, EC. 4.2.1.1) are an expanding family of zinc-containing enzymes
catalyzing the reversible hydration of CO <sub>2 </sub> in a two-step reaction to
yield HCO <sub>3 </sub> <sup>- </sup>and H <sup>+ </sup>. These enzymes play
important roles in several physiological/pathological processes. The aim of
this study is to evaluate <i>in vitro </i>
the effects of these drug active substances which use which use for treatment
of Alzheimer disease on CA I and II isoenzyme. CA I and II isoenzymes from
human blood have been purified using Sepharose-4B-l-tyrosine-sulfanilamide
affinity chromatography method. The CA I isoenzyme was purified ~122.2-fold
with a yield of 61.7%. The CA II isoenzyme was purified ~807.5-fold with a
yield of 60%. rivastigmine was showed competitive inhibition and galantamine
was showed uncompetitive inhibition for CAI. Both of these drug active
substances were showed uncompetitive inhibition for CAII. K <sub>i </sub>values
were determined for rivastigmine CA I: 0.79 µM; CA II: 1.08 µM and for
galantamine CA I: 0.41µM; CA II: 0.40 µM. <b> </b>The results obtained in this study galantamine was identified as the most
potent inhibitor. </span> <span style="font-family:Georgia, serif;"> </span> </p> <p> </p>}, number={1}, publisher={Erzincan Binali Yildirim University}